Z-VAD-FMK

製品コードS7023

Z-VAD-FMK化学構造

分子量(MW):467.49

Z-VAD-FMK is a cell-permeable, irreversible pan-caspase inhibitor, blocks all features of apoptosis in THP.1 and Jurkat T-cells.

サイズ 価格(税別)  
JPY 19422.00
JPY 78020.00

カスタマーフィードバック(5)

  • (A) LAN5 cells were untreated (top panels) or treated with 50 µM of the caspase inhibitor Z-VAD-FMK (bottom panels). Cells were co-treated with nothing (No Rx), 1 µM GSK-J4, or 1 µM venetoclax for 48 hours and assayed for apoptosis by flow cytometry.

    Science, 2018, 10(441), doi: 10.1126/scitranslmed.aao4680. Z-VAD-FMK purchased from Selleck.

    After treatment with 1.5 g/l matrine in the presence or absence of 10 nM Baf A1 or 20 nM rapamycin or 10 lM z-VAD-FMK (zVAD) for 24 hrs, the cell viability was measured by CCK-8 assay. Results were expressed as mean±S.E.M. representing at least three independent experiments. *P < 0.05, versus matrine alone group.

    J Cell Mol Med, 2017, 21(6):1171-1181. Z-VAD-FMK purchased from Selleck.

  • (A and B) Western blot analysis examining the effect of zVAD-fmk on the icaritin-induced apoptosis. The caspase inhibitor zVAD-fmk could significantly decrease the icaritin-induced cleaved caspase-3 expression. β-Actin protein levels indicate that an equal amount of protein was loaded into each lane.n=3. Mean±SD. bP<0.05, compared to the control group. eP<0.05, compared to the icaritin-treated group.

    Acta Pharmacol Sin 2014 35(4):531-9. Z-VAD-FMK purchased from Selleck.

    Active caspase-3 expression analysis. SW1116 cells were treated with ZBH-1205, CPT-11 and SN38 at 25 μmol/L for 48 h, in the presence or absence of Z-VAD-FMK (50 μmol/L, 1 h ahead of time). *P= 0.0345. Z-VAD-FMK(-) vs. Z-VAD-FMK(+). E: Cell cycle analysis. F: Apoptosis analysis. #P=0.0259. Z-VAD-FMK(-) vs. Z-VAD-FMK(+). ALL experiments were repeated three times.

    Arch Biochem Biophys, 2016, 604:74-85.. Z-VAD-FMK purchased from Selleck.

  • Effect on the RAS of CFZ, z-VAD-fmk, or CFZ + z-VAD-fmk treatments administered 5 or 12 days after C26 inoculation and control groups. Western blot analysis of ATF2 and pATF2. CP, ZP and UP were treated for 5 days; CT, ZT, UT and CC were treated for 12 days. CFZ (CP), z-VAD-fmk (ZP), CFZ + z-VAD-fmk (UP), PBS only (CC), healthy control (HC).

    Med Oncol, 2015, 32(4): 538 . Z-VAD-FMK purchased from Selleck.

製品安全説明書

Caspase阻害剤の選択性比較

生物活性

製品説明 Z-VAD-FMK is a cell-permeable, irreversible pan-caspase inhibitor, blocks all features of apoptosis in THP.1 and Jurkat T-cells.
特性 A key compound for apoptosis studies.
ターゲット
Pan-caspase [1]
(THP.1, Jurkat T-cells)
体外試験

Z-VAD-FMK (10 mM) inhibits apoptosis in THP.1 cells. Z-VAD-FMK (10 μM) inhibits activation of PARP protease activity in control THP.1 cell lysates. Z-VAD-FMK (10 mM) inhibits the processing of CPP32 in intact THP.1 and Jurkat cells. [1] Z-VAD-FMK (50 μM) cotreatment abolishes the apoptotic morphology of camptothecin-treated HL60 cells. Z-VAD-FMK (50 μM) blocks camptothecin-induced DNA fragmentation in HL60 cells. [2] Z-VAD-FMK (50 μM) inhibits cell death following dSMN dsRNA-induced apoptosis in S2 cells. Z-VAD-FMK (50 μM) increases the percentage of transfected cells surviving from 26% to 63% in S2 cells. [3] Z-VAD-FMK (> 100 μM) enhances TNFα-induced neutrophil apoptosis, lower concentrations (1-30 μM) completely blocks TNFα-stimulated apoptosis in human neutrophils. [4] Z-VAD-FMK (10 mM) inhibits apoptosis in anterior stromal keratocytes. Z-VAD-FMK (10 mM) inhibits apoptosis in anterior stromal keratocytes detected with the TUNEL assay. [5]

細胞データ
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
GC1a NUXpUW4{SXCxcITvd4l{KEG|c3H5 NHnVU5g2OM7:TR?= M2C2d|I1cA>? NUjDRYtocW6maXPheIV{KGFicILveIVkfGm4ZTDl[oZm[3RiYXfhbY5{fCCndH;wc5Nq\GV? NVmzO414OjZzNkmwO|U>
HGL5 MUfBdI9xfG:|aYOgRZN{[Xl? NEPpUFg2OM7:TR?= MnzzNlRp NYK1R4FGcW6maXPheIV{KGFicILveIVkfGm4ZTDl[oZm[3RiYXfhbY5{fCCndH;wc5Nq\GV? MUmyOlE3QTB5NR?=
HepG2 NF[wdW5CeG:ydH;zbZMhSXO|YYm= MV2yNO69VQ>? Mn6yNYg> NHz1S4ZifHSnboXheIVlKHSqZTDhdI9xfG:2aXOgbY5lfWO2aX;uJI9nKEmLST2xNOKh MUmyOlE3PDd7NR?=
BEL-7402 NU[xVYZWSXCxcITvd4l{KEG|c3H5 NXu2Sms6OjEQvF2= MVyxbC=> MlXLZZR1\W63YYTl[EB1cGViYYDvdJRwfGmlIHnu[JVkfGmxbjDv[kBKUUlvMUFCpC=> NE[0W5MzPjF4NEe5OS=>
CEF NHzPXmdMcW6jc3WgRZN{[Xl? NE\wbYQxNDN|LE[3MFExOM7:TR?= NYLh[GhuOTWvaX6= NUL1NVU2\G:5bj3y[Yd2dGG2ZYOgVHIh\W68eX3lJIFkfGm4aYT5JJRwKDRy78{FJIF1KDFyMN88US=> MXiyOlExOjN|OR?=
SP2/0 MUfBdI9xfG:|aYOgRZN{[Xl? MnrxNVAx|ryP M{fyNVFp MlPTSG1UVw>? NUiz[Gp5[myxY3vzJJRp\SCjcH;weI9{cXNib3[gV3AzNzBiY3XscJM> NH;GeXUzPjB5NEezNi=>
HUVEC-2c MXjBdI9xfG:|aYOgRZN{[Xl? MV61NO69VQ>? NWPMcG1NPmh? NF;wVmxl\WO{ZXHz[YQhfGinIH;4MWxFVC2rbnT1Z4VlKGG3dH;wbIFogQ>? M2fZOFI3ODJzN{K5
U1 NXXCOI9YSXCxcITvd4l{KEG|c3H5 MlT2NE0yODEQvF2= MXyybC=> MlKzdoVlfWOnczDkdpVoNWmwZIXj[YQh[XCxcITvd4l{KGGwZDDzeYJ{\XG3ZX70JGhKXi1zIILldIxq[2G2aX;uJIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXy MUiyOVk5ODl2Mh?=
ACH-2 M3fsdGFxd3C2b4Ppd{BCe3OjeR?= M{XSclAuOjByzszN NH71fWEzcA>? NVexTGFEemWmdXPld{BlenWpLXnu[JVk\WRiYYDvdJRwe2m|IHHu[EB{fWK|ZYH1[Y51KEiLVj2xJJJmeGyrY3H0bY9vKGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz NYj2V|J5OjV7OEC5OFI>
U1 MX\LbY5ie2ViQYPzZZk> MmTpNVAx|ryP MkfTNog> M{LZZ4lvcGmkaYTzJINie3Cjc3WtNy=> MVOyOVk5ODl2Mh?=
A549/V16 MYHBdI9xfG:|aYOgRZN{[Xl? M4m2bFUx|ryP M1nG[lFp MmT3doVxemW|c3XzJHRIN1SPLXnu[JVk\WRiYYDvdJRwe2m| MX2yOVk1PjB|Mx?=
SGN MlfMRZBweHSxc3nzJGF{e2G7 NYSz[pU4OjCvTR?= MoPyOFhp MoC2bIF{KG6xIHnu[ox2\W6lZTDvckBCUUZuIHPhcJBicW5iZYjwdoV{e2mxbjDvdkBk\WyuIHHwc5B1d3Orcx?= M4exRlI2QDd2NkOz
HCT116  MnSxRZBweHSxc3nzJGF{e2G7 NXjsUHZFPTEQvF2= NHXkc2IzcA>? NVrmdnZmcW6qaXLpeJMhfGinIHPlcIwh\GWjdHigbY5lfWOnZDDifUBFTF[S MYiyOVg3QDhzOB?=
DTK-SME Mn\ERZBweHSxc3nzJGF{e2G7 NWX1PIV4PTEQvF2= NIi1cXozcA>? M1vDPWROW09? MorsdIFzfGmjbHz5JIlvcGmkaYTzJJRp\SCjcH;weI9{cXNiaX7keYNm\CCkeTDieZBqfmGlYXnu[S=> NE\HUGkzPTh2M{i5Oy=>
HL-60 MYHBdI9xfG:|aYOgRZN{[Xl? MXK1NO69VQ>? MXm0PIg> MnzSdoVlfWOnczDj[YxtKGSnYYToJINifXOnZDDifUBUU0lvSVmgeJJm[XSvZX70xsA> NGfBW|MzPTh{NEC0Ny=>
U937 MlvrRZBweHSxc3nzJGF{e2G7 NX;Se2xPPTEQvF2= MYK0PIg> NXy2OYkyemWmdXPld{Bk\WyuIHTlZZRpKGOjdYPl[EBjgSCVS1mtTWkhfHKnYYTt[Y51yqB? MXGyOVgzPDB2Mx?=
A549 Mn2zRZBweHSxc3nzJGF{e2G7 Mn\ENlAh|ryP MmH0NlRp NXz4fmlVemWmdXPld{Bk\WyuIHTlZZRpKGOjdYPl[EBjgSCKRlPQJJRz\WG2bXXueC=> MV2yOVc6PDF2OR?=
HeLa MYfBdI9xfG:|aYOgRZN{[Xl? MnHRNVDPxE1? NHKxTWE1QGh? MkLh[IVkdGmwZYOgeIhmKHKjdHWgc4Yh[XCxcITvd4l{KGS{YX3heIlk[WyueR?= MV:yOVc4OjV2NR?=
SGC-7901 MVTBdI9xfG:|aYOgRZN{[Xl? Mnz3NlDDqM7:TR?= MWixbC=> Mn;WbY5pcWKrdIOgeIhmKGOnbHyg[IVifGhiaX7keYNm\CCkeTDvfIFtcXCuYYTpci=> NFvTUJUzPTd4N{C3Oi=>
MCF-7 MknwRZBweHSxc3nzJGF{e2G7 NUnBTIRQOTEQvF2= M{T4fVJp NEHqcWpqdmirYnn0d{B1cGViY3XscEBl\WG2aDDpcoR2[2WmIHL5JFND NUD3b2U5OjV5MkKxNVQ>
A549 NV\yUotUSXCxcITvd4l{KEG|c3H5 M{\YNlExKM7:TR?= NX7tZoZSOjSq NHjrbFdFVVOR NISwenNxem:vb4Tld{BJSkNvdILlZZRm\CCDNUS5JINmdGxic4Xyeol3[WxiJjDheJRmdnWjdHXzJJRp\SClbHXheoVlKFCDUmCg[ZhxemW|c3nvci=> Mlf5NlU3QDN3Nki=
U87 M3\ReWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWHsVldCPTEQvF2= NIH2TJIycA>? M2DlSZJm[2:4ZYLzJINmdGxiZ4Lve5RpKG[{b32gWG1bKHS{ZXH0cYVvfA>? NW\Md5A5OjV4OEG2Olg>
Neocortical Neuron NVHCTHR3VmW3cn;0c5hq[2m2eTDBd5NigQ>? NXjPdIZROTByzszN M3j0WFFp NX:5U29Z[W62YXfvcol7\XNiSH;pZY1q\GViQT3JcoR2[2WmIF7leZJwfG:6aXPpeJk> M4L5WFI2Pjd3MECx
Primary human placental cytotrophoblasts MoDzRZBweHSxc3nzJGF{e2G7 MXizNO69VQ>? MU[yOIg> MYDEUXNQ MoDQdoV3\XK|ZYOgeIhmKGmwaHnibZRqd25ib3[gNVHPui2KU1SyJIJ6KHS{aXPsc5NidsLi MmH0NlU3PDJ3OUK=
MM MUTBdI9xfG:|aYOgRZN{[Xl? NH\KcWM2OM7:TR?= NELIO4szOG2rbh?= MVrwZZJ1dHliaX7obYJqfHNiU1jLMYlv\HWlZXSgJINmdGxiZHXheIg> MmrrNlU2OzByOUi=
DLD1 MVTBdI9xfG:|aYOgRZN{[Xl? NVrMTHN1OjEEoN88US=> MoDtNYg> NX6zVmlHeGG{dHz5JJJmfmW{c3XzJINmdGxiYYDvdJRwe2m|IHPheZNm\CCkeTDXV3Ay NGXh[IkzPTV{NEK0Oi=>
MDA-MB-231 NGCxNmhEgXSxdH;4bYNqfHliQYPzZZk> NX;5NJVoOTEQvF2= M1zFflFp NEf1bmhifWevZX70d{Bk\WyuIHTlZZRpKGGodHXyJGNJXUFidILlZZRu\W62 NHvqfYEzPTV{MUWwNS=>
MKN28 MoLmRZBweHSxc3nzJGF{e2G7 MnjNNVDPxE1? NXnod29XOzCvaX6= NV:2SVRxTE2VTx?= MYrpcohq[mm2czDUUmYu|rFicHz1d{BEUFhvaX7keYNm\CCjcH;weI9{cXN? MYqyOVUyOzl4MB?=
HL-60 Ml\XR5l1d3SxeHnjbZR6KEG|c3H5 M3OxdVExOM7:TR?= NEXyRYYycA>? NYfjXVJ6TE2VTx?= MXRCpIlueHKxdnXzJJZq[WKrbHn0fUBw\iCWQ17Bd{11emWjdHXkJINmdGy| NYS1c4hvOjV3MEK5N|I>
AGS MlfTRZBweHSxc3nzJGF{e2G7 MV[xNO69VQ>? MkfwNYg> NI\n[|FxemW4ZX70d{BkfXKldX3pck1qdmS3Y3XkJINt\WG4YXflJI9nKGOjc4Dhd4UuOyxiLUisJIFv\CBvOTDwdo91\Wmwcx?= MYqyOVQ6OjJzNB?=
A549  NXnpTnJzSXCxcITvd4l{KEG|c3H5 NVi2Z4kxOTEQvF2= M1PrdVI1cA>? MnXqZoxw[2u|IFTNRXMucW6mdXPl[EBkdGWjdnHn[UBw\iClYYPwZZNmNTNiYX7kJHBCWlBiYX7kJIFxd3C2b4TpZ{Bk\WyuIHTlZZRp NIHO[WwzPTR|NEm4PS=>
INS-1 NF;ReY5CeG:ydH;zbZMhSXO|YYm= MkXXOVDPxE1? NWXFVXlqPmh? M4PkcGROW09? MUDk[YNz\WG|ZYOgeIhmKHC{b4DvdpRqd25ib3[g[YFzdHliYYDvdJRwfGmlIHPlcIx{yqB? Mn3yNlU1OzB6OUe=
Primary hepatocytes  MnPJRZBweHSxc3nzJGF{e2G7 NILj[XE2OM7:TR?= NWXPPGZ[OTiq NWLPWFBLcW6qaXLpeJMh[XCxcITvd4l{KG:oIHjldIF1d2O7dHXzJIlv\HWlZXSgZpkhSWO2IFSgZY5lKFSQRj5OtS=> MWCyOVQxPzV|OB?=
L929-A  M1z4SWN6fG:2b4jpZ4l1gSCDc4PhfS=> Mli2NlDDqM7:TR?= MVyyOIg> MY\pcohq[mm2czDUUmbPuS2rbnT1Z4VlKGOnbHyg[IVifGh? NI\uflczPTN7OEW0NC=>
L929-N NHSxPW1EgXSxdH;4bYNqfHliQYPzZZk> M2S1SlIxyqEQvF2= NIrGdG8zPGh? MnH0[Y5p[W6lZYOg[IVifGhidnnhJIF2fG:lcnnu[UBVVkcQsTDwdo9lfWO2aX;u NGm3ZWYzPTN7OEW0NC=>
Cytotoxicity Assay NVPCPG9kS2WubDDWbYFjcWyrdImgRZN{[Xl? M1fuWVIx|ryP Ml7sOFhp MVnwdoV3\W62IF3IUWQucW6mdXPl[EBk\WyuIHTlZZRp M4fZR|I2Ozl{MUG2
COS7 MVPLbY5ie2ViQYPzZZk> MVyxNO69VQ>? MV:yOIg> MlzMbY5kemWjc3XzJINie3Cjc3WgN{84KGGldHn2bZRq\XN? NYn6U3c4OjV|OESwNlU>
COS7 M{XPb2Fxd3C2b4Ppd{BCe3OjeR?= M2HOfVEx|ryP NXjXUVdWPDiq NYnlZ4ZmeGG{dHnhcIx6KHC{ZY\lcpRm\CCIQ{GwNU1qdmS3Y3XkJINmdGxiZHXheIg> NUX3SFR4OjV|OESwNlU>
A375 NHS0RpRCeG:ydH;zbZMhSXO|YYm= NIm4dlY{OM7:TR?= MoO1Nog> MXXwdoV3\W62czD0bIUh\HK3Zz3pcoR2[2WmIGDBVnAh[2ynYY\h[4U> NWDFXW51OjV|N{[xNVU>
A549 M130WGFxd3C2b4Ppd{BCe3OjeR?= M132WFUx|ryP NHnVOI4zPGh? NUDwZm1IemW4ZYLz[ZMhemmkb4PvcYUh[mmxZ3Xu[ZNqeyCjbnSgZZBweHSxc3nzJINifXOnZDDifUAhS2iran;u[4Ridg>? MXKyOVM1QTd6MR?=
A549 MXjBdI9xfG:|aYOgRZN{[Xl? NEXDVGYzNjVvMkZOwG0> Mn7nNYg> MmWx[IVkemWjc3XzJJRp\SCyb4D1cIF1cW:wIH;mJIFxd3C2b4TpZ{Bk\WyuczDk[ZBmdmRib36gZ49v[2WwdILheIlwdnN? Ml7PNlU{PDJ2Mke=
 NBL-W-S  Mo\lRZBweHSxc3nzJGF{e2G7 M4\GOVUx|ryP M4ns[VFp M17MNoZ2dGy7IILld4N2\XNiY3XscEB3cWGkaXzpeJkh[W[2ZYKgS2FPXC14MTD0doVifG2nboS= NE\3OIEzPTN{M{KyNi=>
Caki-1  Mn;URZBweHSxc3nzJGF{e2G7 MkHLOFDPxE1? NF[weZA1QGh? NYr0ZW9MemWmdXPld{B1cGViboXtZoVzKG:oIFHucoV5cW5iVj3wc5NqfGm4ZTDj[Yxtew>? NV;HVWZVOjV{N{mxPVE>
769-P MmjqRZBweHSxc3nzJGF{e2G7 NEm3VmI1OM7:TR?= MkHIOFhp NXvMUldyemWmdXPld{B1cGViboXtZoVzKG:oIFHucoV5cW5iVj3wc5NqfGm4ZTDj[Yxtew>? MmXkNlUzPzlzOUG=
H9c2 M1mzdWFxd3C2b4Ppd{BCe3OjeR?= M2jMW|Ux|ryP MWixbC=> M1TZZolvcGmkaYTzJGRQYC2rbnT1Z4VlKGOjc4Dhd4UhOyCjY4TpeoF1cW:wIHL1eEBvd3RidHjlJIxwe3Nib3[gZ4VtdHN? MXKyOVI5OzhzOR?=
K562 M4XNV2Fxd3C2b4Ppd{BCe3OjeR?= NIewZms2OM7:TR?= NUPQOWNiPGh? NXnNWJQ2cW6qaXLpeJMhUmGlLVGtbY5lfWOnZDDj[YxtKGGyb4D0c5Nqew>? MVSyOVI1OTZzOR?=
L929 M2Dp[WFxd3C2b4Ppd{BCe3OjeR?= NHjEUlgyOM7:TR?= M1zBNVZp NV7KPIJScW6mdXPld{Bv\WO{b4D0c5NqeyC5aYToJHRPTg>? Mke3NlUyQTV4NkC=
A549 NHrr[INCeG:ydH;zbZMhSXO|YYm= NGn5dHQyOM7:TR?= NXPRcJV{O2h? MWXy[YR2[2W|IHPlcIwh[XCxcITvd4l{KGOjdYPl[EBjgSCSUWG= NFjKSmwzPTF4MU[5PS=>
MCF-7 MV7BdI9xfG:|aYOgRZN{[Xl? M2\6OlIx|ryP NVHyVmtpOmh? NYr3c|hb\GWlcnXhd4V{KEuGUj3zbXJPSS2rbnT1Z4VlKGGyb4D0c5Nqew>? NXXoboRGOjVzOEKyOFA>
OS NYPDVmc4SXCxcITvd4l{KEG|c3H5 NHzvRVQzOC92MN88US=> MVS3Nog> NXn1eFhScW6qaXLpeJMhV1NiY3XscEB3cWGkaXzpeJkhemWmdXP0bY9vKGK7IFO2JINmemGvaXTl MXmyOVE2OjN7OR?=
HUVECs NXjHdoliSXCxcITvd4l{KEG|c3H5 NXS5dJU4OTEQvF2= NGS0[m8zcA>? MYNCpIlvcGmkaYTzJIFxd3C2b4Ppd{BidmRiZnHjbYxqfGG2ZYOgZZV1d3CqYXf5JIlvKESHTm[yMYlv\mWldHXkJGhWXkWFcx?= M3\NVFI2OTN6N{Cz
EA.hy926 MYDBdI9xfG:|aYOgRZN{[Xl? M2DLRVEx|ryP M13lclJp M4DaNOKhcW6qaXLpeJMh[XCxcITvd4l{KGGwZDDmZYNqdGm2YYTld{BifXSxcHjh[5khcW5iRFXOWlIucW6oZXP0[YQhTUFwaIm5NlY> NF\ud4MzPTF|OEewNy=>
Ebs MUTBdI9xfG:|aYOgRZN{[Xl? NXPWc5N4OTBvMUCw{txO M2DFNlI1cA>? M4\NVeKhVU2WUzDn[Y5memG2aX;uJJJifGViZHXjdoVie2WmIHHzJJRp\SClb37j[Y51emG2aX;uJI9nKHpvVlHEMoZucyCrbnPy[YF{\WR? MoW0NlUyOzR6MUe=
Jurkat MkTTRZBweHSxc3nzJGF{e2G7 NGLieoEzOM7:TR?= M1m4bFI1cA>? MmLYSG1UVw>? Mom3dIFzfGmjbHz5JIlvcGmkaYSgZ4VtdCCmZXH0bEBw\iCMdYLrZZQh[2WubIOgbY5lfWOnZDDifUAyODB3OD3GOEBkd22kaX7l[EB4cXSqIG\QReKh MXOyOVEzODd{Mx?=
K562 NELQ[FRCeG:ydH;zbZMhSXO|YYm= MofXNE4yNTIQvF2= NUPwZnlzOWh? M3yz[olvcGmkaYTzJINt\WG4YXflJI9nKEiVUEmwJIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXy MknINlUyOTlzOEi=
IMR-32 NHHkOoxCeG:ydH;zbZMhSXO|YYm= M1H3eVQxyqEQvF5CpC=> NE\QU2szcA>? Mojr[IVkemWjc3WgbY4h[XCxcITveIlkKGOnbHzzJINwdXCjcnXkJJRwKFRvMjD0c5hqdg>? M{LB[lI2ODh2N{W1
RPMI 8226 NUHoXZJNSXCxcITvd4l{KEG|c3H5 MX2xNFDPxE1? NHnHfJIycA>? NFnsfFlidG2xc4SgZ49ueGyndHXsfUBjdG:la4OgZ4VtdCCmZXH0bEBk[XW|ZXSgZpkhdmWlcn;zeIF1cW5vMR?= NYO5[VBxOjVyM{e4OVE>
U266  NYnY[ZY4SXCxcITvd4l{KEG|c3H5 MXqxNFDPxE1? MoHCNYg> M4XxO5BienSrYXzsfUBjdG:la4OgZ4VtdCCmZXH0bEBk[XW|ZXSgZpkhdmWlcn;zeIF1cW5vMR?= M4j2W|I2ODN5OEWx
H929  MUPBdI9xfG:|aYOgRZN{[Xl? NX3tTpRPOTByzszN MV6xbC=> M4HnfZBienSrYXzsfUBjdG:la4OgZ4VtdCCmZXH0bEBk[XW|ZXSgZpkhdmWlcn;zeIF1cW5vMR?= MWmyOVA{Pzh3MR?=
MM.1S  M3[5Z2Fxd3C2b4Ppd{BCe3OjeR?= MXuxNFDPxE1? NFPHUmYycA>? M1zLN4Vn\mmlaXXueIx6KHC{ZY\lcpR{KHOxcnHm[Y5q[i2rbnT1Z4VlKGOnbHyg[IVifGhiY3;tZolv\SC5aYToJI5m[3Kxc4TheIlvNTF? MoCxNlUxOzd6NUG=
C6 NEDjWJJCeG:ydH;zbZMhSXO|YYm= M2[wTFUx|ryP NHjFSVA1QGh? MX3wdoV3\W62czD0bIUhdG:|czDv[kBk\WyuII\pZYJqdGm2eTDjZZV{\WRiYomgdJJm\26nbn;sc45m NGHUfo4zPTBzM{S3PS=>
AGS MmLkRZBweHSxc3nzJGF{e2G7 NIHaRWo2OM7:TR?= NFXIWWwzPGh? NUj2bIFW[WKxbHnzbJMh|rJvbHHwZYNpd26nLXnu[JVk\WRiY3XscEBl\WG2aDDhcoQhcW6qaXLpeIVlKGe{b4f0bC=> MXuyOVAxQTZ7OB?=
HeLa  NVzHOoNDSXCxcITvd4l{KEG|c3H5 NFKyXmw1OM7:TR?= MnH6NlRp NXTxbJpIcW6qaXLpeJMhfGinIHnuZ5Jm[XOnZDDhdI9xfG:|aYOgbY5lfWOnZDDifUB{cVKQRkGyNS=> M{HZcFI1QTJ6Nki1
THP-1  MWfBdI9xfG:|aYOgRZN{[Xl? NIWweFkyOM7:TR?= M3X6dVFp NYTQWGFYemWmdXPld{BieG:ydH;zbZMhcW6mdXPl[EBjgSCDTFGtV2RVyqB? MVuyOFkzOzZ3Mx?=
P815  M3nN[mFxd3C2b4Ppd{BCe3OjeR?= NIn5Z3cyODBiwsXN MoDMNVJp NH;NdZhFVVOR MWLpcohq[mm2czD2bZJ2ey2rbnT1Z4VlKGGyb4D0c5Nqew>? M1v3cFI1QTJ|Mkez
HCT116 NFG3WJJCeG:ydH;zbZMhSXO|YYm= MoTiNlDPxE1? MnLZNlRp NXzqVoRs[WK{b3fheIV{KG:oIGTRMYlv\HWlZXSgZZBweHSxc3m= MmTCNlQ5QTB2NEm=
SW1116  MoizRZBweHSxc3nzJGF{e2G7 Mm\VNVAhyrWP NF;kR4kycA>? MnO0SG1UVw>? NHfZbFhz\XO2cnHpcpMh[2WubDDhdI9xfG:|aYOgbY5lfWOnZDDifUBo\W[rdHnubYIheGy3czDk[YNqfGGkaX7l MoizNlQ5PzR{OE[=
LOVO M1HFSGFxd3C2b4Ppd{BCe3OjeR?= NFjNV4EyOCEEtV2= NUnmU3pDOWh? NFrPfZBFVVOR NGTpOJNz\XO2cnHpcpMh[2WubDDhdI9xfG:|aYOgbY5lfWOnZDDifUBo\W[rdHnubYIheGy3czDk[YNqfGGkaX7l MWWyOFg4PDJ6Nh?=
SNU449  M3rpUWFxd3C2b4Ppd{BCe3OjeR?= M{XlbVIx|ryP NWnlVJhjPDiq M4jQV2ROW09? NYTIcHhx\GWlcnXhd4V{KG2rUj20OVEucW6mdXPl[EBieG:ydH;0bYM> MWKyOFg1OTZ|OB?=
Caco-2 NHvTdmpCeG:ydH;zbZMhSXO|YYm= M4DMNFQx6oDLzszN NFmxRWM1cA>? M3rMdpBz\X[nboTzJHNVNTdvaX7keYNm\CCcTz2xJINp[W6pZYOgZY5lKFSHUjDkdo9x NYrLWYhxOjR6MkKxPFM>
macrophage M4LlPWNmdGxiVnnhZoltcXS7IFHzd4F6 M17jdlAuOjByzszN MnrFNlRp NETJUXpqdmS3Y3XzJHRPTi1iYX7kJHJqeDNvZHXw[Y5l\W62IH7lZ5JweHSxc3nzJIlvKG2jY4LvdIhi\2V? NX;meJlUOjR5OUm1OlU>
AGS  NHLLdIVCeG:ydH;zbZMhSXO|YYm= MUCyNO69VQ>? M13N[VEzcA>? M4PaWmROW09? NIL6cYRz\WS3Y3XzJJRp\SCrbnT1Z5Rqd25ib3[gZZBweHSxc3nzJIlvKHKnc4DvcpNmKHSxIITo[UBGfE:DYzDmdoFkfGmxbjDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= MoDFNlQ4QDl5MEO=
LCC9  M2TSOmNmdGxiVnnhZoltcXS7IFHzd4F6 MUSxNFDPxE1? MYK1[C=> Mle0Zoxw[2u|IHPlcIwh\GWjdHigbY5lfWOnZDDifUBkd22kaX7heIlwdiCOMUegZY5lKGOqbH;yc5F2cW6n NGfJdZQzPDd6NUK1Oi=>
U937  M4TjSo5m[3KxcITvd4l{KEG|c3H5 M1noVVExyqEQvF2= MVmzNOKhdWmw NVfG[FlxcW6mdXPld{Bv\WO{b4D0c5NqeyClb33ibY5mKHerdHigWG5H MmHLNlQ4PzN5NU[=
T cell MonDR4VtdCCycn;sbYZmemG2aX;uJIF{e2G7 NFz4ZW4xNTFyMN88US=> M4HkO|czcA>? MlLvTWM2OD15MDFOwG0tKGmwaHnibZR{KGGwdHmtR2Q{NWmwZIXj[YQhXCClZXzsJJBzd2yrZnXyZZRqd25iaX6gVGJOS3N? M2nQe|I1PzZ6N{C3
HeLa  M{XPdGFxd3C2b4Ppd{BCe3OjeR?= M1O1XFUx|ryP NXr2SYNLPzKq NHvyUFlFVVOR NILQRZpxemW4ZX70d{BieG:ydH;zbZMhcW6mdXPl[EBjgSClb33wc5Vv\HQEoEJihLM2 M{nkZlI1PzV2N{i2
HeLa  NFm5PY1CeG:ydH;zbZMhSXO|YYm= NH7vfHgyODEQvF2= MknhNlRp NX3XVlB6e3WycILld5NmeyC{YYTlJI9nKGOnbHyg[IVifGhiaX7keYNm\CCkeTDveoVz\XiycnXzd4lwdiCxZjDHOVlUKG:{IFe3NXIheDF3MHfseYVlyqB? MWSyOFczOjR4OB?=
IEC-6  NEjmWYtCeG:ydH;zbZMhSXO|YYm= MmLaNVDPxE1? MWOyOIg> M1rBbJBz\X[nboTzJHRk\EFvaX7keYNm\CClYYPwZZNmNTNiY3zlZZZi\2ViYX7kJO6zNWOjdHXubY4h\GWpcnHkZZRqd25? MW[yOFcyOTV5MR?=
HCT116 M1XsR2Fxd3C2b4Ppd{BCe3OjeR?= MVqyNO69VQ>? M1PRXVI1cA>? Mk\HbY5pcWKrdIOgeIhmKGOnbHygZZBweHSxdHnjJIlv\HWlZXSgZpkhYUyWMkC1 MmDsNlQ4OTN6MUK=
L02 MXnBdI9xfG:|aYOgRZN{[Xl? Mn3wNlDPxE1? NIjrOnQycA>? MnLpdJJmfmWwdIOgeIhmKGOnbHygZZBweHSxc3nzJIlv\HWlZXSgZpkhVUWKUB?= MoPhNlQ4ODZ2NkG=
A375 MXnBdI9xfG:|aYOgRZN{[Xl? MXyyNO69VQ>? M2XTNlI1cA>? NFfv[mRz\X[ncoPld{BlcWOrdILpco9v\SCELXnu[JVk\WRiYYDvdJRwe2m| MUKyOFY6QTFzMR?=
HDPC NFXjb2VCeG:ydH;zbZMhSXO|YYm= M{DPO|UxyrWP M{Szb|I1cA>? MnnWbY5pcWKrdIOgUm8ucW6mdXPl[EBieG:ydH;zbZM> NWO0N2pLOjR4M{S1PVM>
A549 NUTJO|hwSXCxcITvd4l{KEG|c3H5 NXfEeWxmPTEEtV2= MV6ybC=> NH63e41FVVOR MXXwdoV3\W62czD0bIUhcHmyb3TpdIxwcWRiRF7BJINwdnSnboSgdIhie2ViaX7keYNm\CCkeTDj[ZBp[WyxY3jyc41qdg>? M1vqS|I1PTh6MUO1
 BV-2 MVjBdI9xfG:|aYOgRZN{[Xl? NXrEcXNXOjEQvF2= NHzYbIkzcA>? NWLn[no3e3WycILld5NmeyCXVj3pcoR2[2WmIHPodo9u[XSrbjDlfJRzfXOrb36gZY5lKGSrbHH0bY9vKG:oIITo[UBvfWOuZXHyJIVvfmWub4Dl M{DnO|I1PTV6MUG4
HT-29  MmiyRZBweHSxc3nzJGF{e2G7 NWPBR5ZzPTEQvF2= NVfTcIRJPDiq MXPicI9kc3NidHjlJIFxd3C2b4Ppd{BqdmS3Y3XkJIJ6KGujZX3w[oVzd2x? MnHPNlQ2PDlzN{W=
A549 M17ndWFxd3C2b4Ppd{BCe3OjeR?= MX[1{txO M3WxclI1cA>? MmHsd5VxeHKnc4Pld{A3\cLiKFLLNVAxPDBrLXnu[JVk\WRiYYDvdJRwe2m|wrC= MnjxNlQ2Ojl6N{G=
MIA-PaCa-2 NHT3ZpdCeG:ydH;zbZMhSXO|YYm= NEPxU3EzPGh? NHPpOHRjdG:la4OgZ4xm[X[jZ3Wgc4Yh[2G|cHHz[U0{KGmwZIXj[YQh[nliYn;0bEBCNTR2M{[1OEBidmRicHHjcIl1[XinbB?= M4PjWFI1PTFyOUmy
Caki-1 NV7GXnM5SXCxcITvd4l{KEG|c3H5 M{HsZ|Ix|ryP MnHhNYg> MYrpcohq[mm2czDTR3AucW6mdXPl[EBieG:ydH;zbZM> MV2yOFUxPDZ6MR?=
CLL NUDrdJk5SXCxcITvd4l{KEG|c3H5 M2rEelI2|ryP MXuxbC=> NH7lNI5x[XK2aXHscJkh[myxY3vzJG1NVjJ{M{itbY5lfWOnZDDj[YxtKGGyb4D0c5Nqew>? NHvDbHYzPDR4N{[zOC=>
SGC-7901 Ml[5RZBweHSxc3nzJGF{e2G7 M172[lEx|ryP MYCyOIg> NF\hfZFxem:vb4Tld{B1cGViQ1fJTU1qdmirYnn0[YQh[2WubDDndo94fGhiaX6gV2dENTd7MEGgZ4VtdHN? M1j0VFI1PDV2NEi4
k1735 NY\Mclc5SXCxcITvd4l{KEG|c3H5 MVuyNQKBkc7:bR?= NF72d|M1cA>? M1WxR4lvcGmkaYTzxsBU[Wyvb37lcIxiNWmwZIXj[YQh[XCxcITvd4l{ NW\GSnFiOjR2NUGxNVY>
HaCaT  NVG0S21uSXCxcITvd4l{KEG|c3H5 MXWxNFDPxE1? MnraNYg> Mo[zZox2dnS|IGXWRk1qdmS3Y3XkJIFxd3C2b4Ppd{BqdiCKYVPhWEBk\Wyucx?= MXeyOFM2Pjl7Nx?=
podocytes NHGzOHNCeG:ydH;zbZMhSXO|YYm= MWGyNFDPxE1? Ml;ZOog> NELTW2hqdmirYnn0d{BieG:ydH;zbZMhcW6mdXPl[EBjgSB|LEStSGdG NWTocHlWOjR|M{e3O|c>
 KB NV3Ob5l2SXCxcITvd4l{KEG|c3H5 MkfYOVDPxE1? NVzlT2c3OjSq NHnJZopqdmirYnn0d{BNcWOxLVGtbY5lfWOnZDDjZZNx[XOnLUOgZY5lKFCDUmCgZYN1cX[jdHnvci=> NWr2e|lIOjR|M{e0PVI>
 HepG2  NITWZ2VCeG:ydH;zbZMhSXO|YYm= MUixNO69VQ>? M2\le|I1cA>? Ml3KdoVlfWOnczD2bY1mdnSrbjDjcIVifmGpZTDjZZV{\WRiYomgUHBU NGWyU20zPDN{NUixOi=>
fetal rat lung fibroblasts  NVPxPYpYU2mwYYPlJGF{e2G7 MYe4NO69VcLi NWDVTFhUOWh? NF3vUWJqdmirYnn0d{BE[XOyYYPlMVMh[WO2aY\peJnDqA>? NXTtRXluOjR|MUSxN|U>
PDL fibroblasts M1ixdmtqdmG|ZTDBd5NigQ>? M2rGelgx|ryPwrC= NHjZcHEycA>? NFLIU2FqdmirYnn0d{BE[XOyYYPlMVMh[WO2aY\peJnDqA>? M4rRblI1OzF2MUO1
MB49 M{fscmFxd3C2b4Ppd{BCe3OjeR?= MX[yNO69VQ>? NIDHPYgycA>? NFjNbVdz\X[ncoPld{BEVS2rbnT1Z4VlKGOnbHyg[IVifGh? MUSyOFI5OjR|Mx?=
5637 MnnzRZBweHSxc3nzJGF{e2G7 MoX3NlDPxE1? MYmxbC=> MVXy[ZZmenOnczDDUU1qdmS3Y3XkJINmdGxiZHXheIg> MX2yOFI5OjR|Mx?=
A549  MXLBdI9xfG:|aYOgRZN{[Xl? MVSxNFDPxE1? Mn\rOFhp M2n1[5N2eHC{ZYPz[ZMhfGinIHHwc5B1d3OrczDjZZV{\WRiYomgdIlx\XKrbnZCpC=> NWXVSGRxOjR{N{KyNFE>
MCC-2 NHPSfHhCeG:ydH;zbZMhSXO|YYm= M3TES|IxKM7:TR?= MXK2bC=> M1zJVGROW09? NVjsO5FD[myxY3vzJIlv\HWlZXSgZpkhe3SjdYLvd5BwemmwZTDhdI9xfG:|aYOgZ4VtdCCmZXH0bC=> MnXMNlQzPjJ4NUi=
ADF MoTXRZBweHSxc3nzJGF{e2G7 MonjOFDPxE1? M4nEfFZp M3HpRYlvcGmkaYTzJIFxd3C2b4Ppd{BqdmS3Y3XkJIJ6KGOqZX3veIhmemGyeTDwcJV{KFqwQ3yy NFXIVoEzPDJ{OEKzNi=>
 U373  MlzsRZBweHSxc3nzJGF{e2G7 MUO0NO69VQ>? MXu2bC=> M1\U[4lvcGmkaYTzJIFxd3C2b4Ppd{BqdmS3Y3XkJIJ6KGOqZX3veIhmemGyeTDwcJV{KFqwQ3yy NIGwRY0zPDJ{OEKzNi=>
RKO-HIPK2i M1\DXGFxd3C2b4Ppd{BCe3OjeR?= MXm0NO69VQ>? M17vW|Zp NE\0T25qdmirYnn0d{BieG:ydH;zbZMhcW6mdXPl[EBjgSClaHXtc5Rp\XKjcImgdIx2eyCcblPsNi=> MlzRNlQzOjh{M{K=
HEC-1B M4TW[WFxd3C2b4Ppd{BCe3OjeR?= NVHV[2JGOjEQvF2= MnHtNYg> NF63bVNz\WS3Y3XzJHRRNWmwZIXj[YQh[XCxcITvd4l{yqClYYPwZZNmNTNiYX7kJINie3Cjc3WtPS=> MVuyOFIyOzN3OB?=
4T1 NGXEcmpE\WyuIG\pZYJqdGm2eTDBd5NigQ>? MnPTNk42NTFyzszN M{\hXVRp M1njZWROW09? NG\kNGtz\XOldXXzJJRp\SCleYTveI95cWOrdImgc4YhPFRzIHPlcIx{KGmwZIXj[YQh[nliU2DEWEBqdiCjIHPvcoNmdnS{YYTpc44h\GWyZX7k[Y51KG2jbn7ldi=> NF23WGIzPDJyNkG2NS=>
OS  M1qxemFxd3C2b4Ppd{BCe3OjeR?= M4jMbFIx|ryP NW\POoZEPGh? NGPYWJRqdmirYnn0d{B1cGViY3XscEBl\WG2aDDjZZV{\WRiYomgVGRV M{XwTFI1OjB2OUO3
RPE M3jrNGFxd3C2b4Ppd{BCe3OjeR?= MWixNFDPxE1? NVL3OlV7PDiq M1e4NpBienSrYXzsfUBqdmirYnn0d{B1cGViY3HsdIFqdi1zIHHu[EAuOiCjY4TpeoF1cW:wIHHzJJdmdGxiYYOgeIhmKGOjc4Dhd4Uh[WO2aY\heIlwdg>? MnzTNlQzODJyNUK=
UD29a NIPiN41CeG:ydH;zbZMhSXO|YYm= M4fkclUx|ryP NEnMT3QzPGh? MVXpcohq[mm2czD0bIUh[2WubDDk[YF1cCClYYXz[YQh[nliTmXUNy=> MnvuNlQyQTB3N{S=
SH-SY5Y  Mlm2RZBweHSxc3nzJGF{e2G7 NXTYbm1sOTEQvF2= NV\LSIQ2OjSq MV3heJRmdnWjdHXzJINie3Cjc3WgZYN1cX[jdHnvckBidmRiY3XscEBl\WG2aDDpcoR2[2WmIHL5JGhPTS1{RFe= MlHENlQyPDV2NkO=
HeLa  M3rtOWFxd3C2b4Ppd{BCe3OjeR?= NFXTc2UyOC9{MN88US=> NIPJ[4MzPGh? NX3qWHdqcW6qaXLpeJMhfGinIHHjeIl3cXS7IH;mJJRp\SCvYXrvdol1gSCxZjD0bIUhdWWvYnXyd{Bw\iC2aHWgZ4F{eGG|ZT3mZY1qdHl? M3vjd|I1OTN5Mk[2
SCCVII  MX\BdI9xfG:|aYOgRZN{[Xl? MnfwNlXPxE1? NWizWZd6OWh? NGrXVHJqdmirYnn0d{B1cGViY3XscEBscWyuaX7nJIFnfGW{IHThd4F1cW6rYh?= NFPifWozPDF{NkS2OC=>
RAW 264.7 MnTvRZBweHSxc3nzJGF{e2G7 M3n3OVIx|ryP MXWxPIg> NF35dZhqdmO{ZXHz[ZMhVEN|LVnJM:6zNWGldHnuJJJifGmxIHPvcZBiemWmIITvJGVEXFZvTV;TJJRz\WG2bXXueEBwdmy7 NYLqOZFqOjRzMU[3NFc>
A549  NHr0bWhCeG:ydH;zbZMhSXO|YYm= NHe2OZgzNjYQvF2= MWeyOIg> M{mxXoRm[3KnYYPld{Bwemmmb37pck1qdmS3Y3XkJIF2fG:yaHHnfUBieyC5ZXzsJIFv\CCOb4PzJI9nKM7Wz5jtJIFte29ib3PjeZJz\WRiZIXybY5oKGG3dH;wbIFocWNicILvZ4V{ew>? M{KydlI1OTB{NUKy
UM-SCC-10A  MnrPRZBweHSxc3nzJGF{e2G7 NIHaS3U2OML3TR?= MUWybC=> MmDtdoVlfWOnczDhdI9xfG:|aYOgbY5lfWOnZDDifUBpcWeqLXTvd4UhcXOxYXzhcpRwdGGldH;u[S=> MVSyOFA6QDd3Mx?=
BGC-823 Mm\uRZBweHSxc3nzJGF{e2G7 MV:xNEDPxE1? NWjlNJdDOjSq M4raNpJm\HWlZYOgeIV1emGwZILpcoUucW6mdXPl[EBieG:ydH;zbZPDqA>? NYHYTlU4OjRyOUi1NVE>
Nalm-6  NV;R[IxiSXCxcITvd4l{KEG|c3H5 NGj3UpYzOM7:TR?= NYCwO5NKPGh? NVHsXpBEcW6qaXLpeJMh[2G|cHHz[U05KGGwZDDjZZNx[XOnLUOgZYN1cX[jdHnvckBidmRiUFHSVE0yKGOuZXH2ZYdm Ml;kNlQxOzl7Nke=
KHOS  M4fVeGFxd3C2b4Ppd{BCe3OjeR?= NXy0[2s6PDEQvF2= NETHem4zPGh? NEjibnVjdG:la4OgeIhmKGmwY4LlZZNm\CClbHXheoFo\SCxZjDjZZNx[XOnLUOgZY5lKFCDUmCgbY5lfWOnZDDifUBDSk2GM9Mg M2nQR|I1ODJ3M{[x
G292 NGLaUW9CeG:ydH;zbZMhSXO|YYm= MmOyOFDPxE1? MoTSNlRp NXixPWJq[myxY3vzJJRp\SCrbnPy[YF{\WRiY3zlZZZi\2Vib3[gZ4F{eGG|ZT2zJIFv\CCSQWLQJIlv\HWlZXSgZpkhSkKPRERCpC=> M1HPPFI1ODJ3M{[x
MG-63 MXnBdI9xfG:|aYOgRZN{[Xl? NE\yeZY1OM7:TR?= NULsRWE6OjSq MUPicI9kc3NidHjlJIlv[3KnYYPl[EBkdGWjdnHn[UBw\iClYYPwZZNmNTNiYX7kJHBCWlBiaX7keYNm\CCkeTDCRm1FO8Li Ml7RNlQxOjV|NkG=
EBV-transformed B cells MVrBdI9xfG:|aYOgRZN{[Xl? M{fER|Ix|ryP MmLwNog> Mn\XSG1UVw>? MnrVZoxw[2u|IHHueIkuS0R6MDDhcoQh[W62aT3DSFg3KGGwdHnic4R6NWmwZIXj[YQh[XCxcITvd4l{ M2TOUVI1ODB6NkK4
IM-9 B M1zm[2Fxd3C2b4Ppd{BCe3OjeR?= NF;xXVYzOM7:TR?= Mk\5Nog> M2[xXWROW09? M4e5ZYJtd2OtczDhcpRqNUOGOECgZY5lKGGwdHmtR2Q5PiCjboTpZo9lgS2rbnT1Z4VlKGGyb4D0c5Nqew>? M3;aO|I1ODB6NkK4
CNE1 MW\BdI9xfG:|aYOgRZN{[Xl? MnX4NlDPxE1? NVTVWWREPDiq M4rVc4Jtd2OtczDMT{1CNWmwZIXj[YQh[XCxcITvd4l{ Mln1NlM6QDVyMkm=
CNE2 NFyyOIZCeG:ydH;zbZMhSXO|YYm= MlPVNlDPxE1? M{Pk[lQ5cA>? MX\icI9kc3NiTFutRU1qdmS3Y3XkJIFxd3C2b4Ppdy=> NWHCV|lGOjN7OEWwNlk>
HL-60 MVzBdI9xfG:|aYOgRZN{[Xl? NHH1V2Q2OML3TR?= MoW2NYg> M{HUWGROW09? NYexNmpYcW6qaXLpeJMh[XCxcITvd4l{KGmwZIXj[YQh[nliQlGxOFU> NFPXdnMzOzl2OEe1NS=>
L929 NEPEd|RCeG:ydH;zbZMhSXO|YYm= NE\i[40yNjJ34pETOeKh|ryPwrC= MWeyOIg> MUnheYdu\W62czDUUmbPuS2rbnT1Z4VlKG6nY4LvdJRwe2m|IHHu[EBifXSxcHjh[5k> NHq0OoczOzl2MUe2PS=>
Jurkat NWDOVGY1S2WubDDWbYFjcWyrdImgRZN{[Xl? NG\K[Y4z|ryP MW[0bC=> NXi3SJBQemW4ZYLz[ZMh\3Kxd4ToJIlvcGmkaYTpc44h[W6mIN8yMYNifGWwaX6g[IVkemWjc3WgZpkhUFNvQWPB MWCyN|g6PjB4MR?=
RAW264.7  MmntRZBweHSxc3nzJGF{e2G7 M{O4WVExKM7:TR?= NH:0[3IzPGh? M{\R[YRm[3KnYYPld{B1cGViYYDvdJRwe2m|IHnu[JVk\WRiYomgS2E> M1Hlc|I{QDJyMkCz
A431  MYTLbY5ie2ViQYPzZZk> MUS0NO69VQ>? NHnGdWwzcA>? MmLBZoxw[2u|IH\pd4V1cW5vaX7keYNm\CClbHXheoFo\SCxZjDjZZNx[XOnczDhcoQhWEGUUB?= NYT6T5VnOjN6MECwOVg>
Jurkat NFXjN4pE\WyuIG\pZYJqdGm2eTDBd5NigQ>? NFm5SFkzPS1zMEFOwG0> MVe2bC=> M2rPfYlvcGmkaYTzJJouTkFvQ13LMYlv\HWlZXSgZ4VtdCCmZXH0bC=> NIHMT2szOzl|M{WzNi=>
COS-7  NIP4SmxHfW6ldHnvckBCe3OjeR?= NYXx[4ZpPTEEtV2= M1POTFI1cA>? MoWxZYZn\WO2czD0bIUheHKxY3Xzd4lv\yCxZjDBWG4yeyC5aYToJJBwdHmTIITyZYN1ew>? M1fvNVI{QTN|MkC4
CAL27 NVHKPVE1SXCxcITvd4l{KEG|c3H5 M2\Db|ExKM7:TR?= NF[wNXQzcA>? MX;zeZBxemW|c3XzJGN2ei2QUIOtdoVlfWOnZDD2bYFjcWyrdImgZpkhfXBidH:gPVAm MmiwNlM6OTd|OU[=
THP-1  M17pXGFxd3C2b4Ppd{BCe3OjeR?= MVSxNE02OM7:TR?= M2fUUVJp NWCyT3l6cW6qaXLpeJMh[XCxcITvd4l{KGmwZIXj[YQh[nlidILpdJRwdGmmZR?= MnLHNlM6ODB{OUm=
K562 MWnBdI9xfG:|aYOgRZN{[Xl? M1KwRVIx|ryP MkXlOFhp NF\3bWlqdmirYnn0d{BieG:ydH;zbZMhcW6mdXPl[EBjgSB2LV3V MXSyN|g4Pjh{Nh?=
HL-60 NEXoNJNCeG:ydH;zbZMhSXO|YYm= NWHBZ2QyOTByzszN M{\1NlI1cA>? NGWweGJqdmirYnn0d{BieG:ydH;zbZMhcW6mdXPl[EBjgSCjYnnleIFv\SCmaYTldpBmdmW|wrC= NF3seHEzOzh4NUe3PC=>
HeLa  M1LZNGFxd3C2b4Ppd{BCe3OjeR?= M4\WOlIx|ryP NVjZc|dmOmh? MXLpcohq[mm2czDEUW1RKGmwZIXj[YQh[XCxcITvd4l{ MWmyN|g3Ozl4Nh?=
U251 MV7BdI9xfG:|aYOgRZN{[Xl? NEj1dFczOM7:TR?= M1LKfFI1cA>? NYjYZpdlcW6qaXLpeJMh[2G|dHnjbY4hcW6mdXPl[EBIOi:PIIDoZZNmKGG{cnXzeEBidmRiYYDvdJRwe2m| MlPxNlM5OTZ6MU[=
HL-60 M2TrXWFxd3C2b4Ppd{BCe3OjeR?= MlnEOVDDvU1? MVm0bC=> NIO3XlBjdG:la4OgeIhmKGOuZXH2ZYdmKG:oIHPhd5Bie2VvMzygMVktKGGwZDDQRXJRKGmwZIXj[YQh[nliNoO= M3jke|I{QDB2N{C2
Ec-109 MYjBdI9xfG:|aYOgRZN{[Xl? MY[xNEDPxE1? Ml\LOFhp M1[4c5JmeHKnc4Pld{BRTS2vZXTpZZRm\CCHYz2xNFkh[2WubDDhdI9xfG:|aYO= NIrMR|gzOzd6Mk[0NS=>
RKO MlXxR4VtdCCYaXHibYxqfHliQYPzZZk> NHLxZ3oyOCEQvF2= M3niTFI1cA>? NUHEOW9scW6qaXLpeJMhfGinIHTlZ5Jm[XOnIH;mJINmdGxidnnhZoltcXS7IHPheZNm\CCkeTDERWI> MnzMNlM4PThyNkS=
T98G NXnwb49pS2WubDDWbYFjcWyrdImgRZN{[Xl? M1vsOVEuOTByzszN MYiyOIg> NV31Z|NXcW2ycn;2[ZMh[2WubDD2bYFjcWyrdImgZ491emWjdH3lcpQhf2m2aDDUVy=> M1HaTlI{PzZ7Mke1
Jurkat MXfD[YxtKF[rYXLpcIl1gSCDc4PhfS=> MX[xNFAuOjByzszN NHKzNWMzPGh? NIrJW5dqdmirYnn0d{BJ[UF2IHnu[JVk\XNiYYDvdJRwe2m|IHTldIVv\GWwdDDv[kBkd26lZX70doF1cW:wwrC= MlTzNlM4OzJ2OEG=
Molt-3  MofjRZBweHSxc3nzJGF{e2G7 MXS1NO69VQ>? NX72bY1vOmh? NWX3XIlPemWmdXPld{Bu\WyjdH;ubY4ucW6mdXPl[EBieG:ydH;zbZM> MmHvNlM4OjVyMUO=
hMSC12 MlnERZBweHSxc3nzJGF{e2G7 MYCxNFDPxE1? NIrTfWU1\A>? MlnpbY5pcWKrdIOgc5N1\W:pZX7pZ{BkfWy2dYLlMYlv\HWlZXSgZ4VtdCCmZXH0bEBidmRiY3HsZ4lncWOjdHnvci=> NEPqOFkzOzZ3N{iyNi=>
HM7  NVfnOJJKSXCxcITvd4l{KEG|c3H5 NEHsXmszOM7:TdMg NGPUU3AycA>? MlnVZoxw[2u|IHHwbYN2dGG{ZX6gRUBi[2W2YYTlMYlv\HWlZXSgZ4F{eGG|ZT2zJIFkfGm4YYTpc44h[W6mIGDBVnAh[2ynYY\h[4U> M2K1fFI{PTh|NEGy
Hep-2  MXHBdI9xfG:|aYOgRZN{[Xl? NUfiRppFOjEQvF5CpC=> MmS0NlRp MmL4SG1UVw>? Mof6ZYxt\X[rYYTld{B1cGViZHXjdoVie2Vib3[gZ4VtdCC4aXHibYxqfHliaX7keYNm\CCkeTDzbYxq[mmwaX6= NH71[oYzOzV6MECzNi=>
HSCs NFq1cpNCeG:ydH;zbZMhSXO|YYm= M2O0XFUx|ryP MUKyOIg> MmL3SG1UVw>? NXficJQ1cW6qaXLpeJMhdmmub4TpcoljNWmwZIXj[YQhTE6DIHThcYFo\SCrbnTpZ4F1\WRiYomgVGFTWCClbHXheoFo\Q>? MXeyN|Q6QTh5NB?=
HL-60  MYrDfZRwfG:6aXPpeJkhSXO|YYm= M17EVVIx|ryPwrC= NVXqVI9tOjSq MW\y[YR2[2W|IITo[UBkgXSxdH;4bYMh\W[oZXP0JI9nKEW{eUW= M4XSNFI{PDl2NEiw
HA M{HuXmFxd3C2b4Ppd{BCe3OjeR?= NVrJWnp3PTEQvF2= MkDyNlRp M{i1eZN2eHC{ZYPz[ZMhfGinIHPs[YF3[WenIH;mJHBCWlBiYX7kJINie3Cjc3WtN{whNTduIHHu[EAuQSCrbnT1Z4VlKGK7IHLvdpRmgm:vaXKvV2FJSQ>? M2HaTlI{PDd3OUW2
C666-1 MV7BdI9xfG:|aYOgRZN{[Xl? Mn3kOVDPxE1? NYf2b2czOjSq NF7TcVF{fXCycnXzd4V{KHSqZTDjcIVifmGpZTDv[kBRSVKSIHHu[EBk[XOyYYPlMVMtKC15LDDhcoQhNTliaX7keYNm\CCkeTDic5J1\XqxbXniM3NCUEF? NHPuZZMzOzR5NUm1Oi=>
Hepa1-6 NFP6NpRCeG:ydH;zbZMhSXO|YYm= M2jNSFUx|ryP M3SzdVJp M{jydYlvcGmkaYTzJIN2emO3bXnuJIFv\CC{ZYP2[ZJifHKxbD3pcoR2[2WmIHHwc5B1d3Orcx?= MmnHNlM1PDZ5NUO=
PLC/PRF/5c MUHBdI9xfG:|aYOgRZN{[Xl? NFH6b2U2OM7:TR?= MYSxbC=> M{TKbZBz\X[nboTzJIFxd3C2b4Ppd{B1emmpZ3Xy[YQh[nliQ1nO MnXlNlM1Ozh6MkS=
HCT116 Mo[2RZBweHSxc3nzJGF{e2G7 NVzpfXNuOTByzszN M3HJdVEvPWh? M1fxU4lvcGmkaYTzJG9{NWmwZIXj[YQh[2WubDDk[YF1cA>? NGrofI0zOzd2NEO1Ny=>
HCEC NGrjbWpHfW6ldHnvckBCe3OjeR?= MnTDOVDPxE1? NF7Ufo84Omh? NV\ye5I3TE2VTx?= MnL5doV{fG:{ZYOgc4YhfGinIH7vdo1idCCKQ1XDJJBp\W6xdInw[S=> NWradWU1OjN5NEKwNVE>
Primary rat cerebral cortical neurons M{DSb2Fxd3C2b4Ppd{BCe3OjeR?= NFzpNGkyODEQvF2= M4rab|Fp M3XocZBz\X[nboTzJGNlNWmwZIXj[YQh[XCxcITvd4l{KGGwZDDj[YxtKGSnYYTo MXuyN|c1OTNzNx?=
MDA-MB-231  NGe5XoNCeG:ydH;zbZMhSXO|YYm= MofQNlXPxE1? Mn\KNlRp NXiyOIdj[WK{b3fheIV{KGO7dH;0c5hq[2m2eTDhcoQh[2ynYY\h[4Uhd2ZiY3HzdIF{\S1|IHHu[EBRSVKSIHnu[JVk\WRiYomgVoc{ MWCyOVM{PzV2NB?=
NLRP3-Tet-on-MC/9  MknRRZBweHSxc3nzJGF{e2G7 M2XyO|ExNTRyzszN M4nSdFEzcA>? NEnSbGRifHSnboXheIV{KHSqZTDj[YxtKGSnYYToJINifXOnZDDifUBESVCVLXHzd49kcWG2ZXSgUmxTWDNibYX0ZY51eyCrbjD0bIUhXGW2LX;uJJN6e3SnbR?= NHmzbHAzOzdyM{O4PS=>
KNS42  NYrkW2o2SXCxcITvd4l{KEG|c3H5 MWC1NO69VQ>? MYSxbC=> M1XnZZJm\HWlZYOgZ4VtdCCmZXH0bEBidmRiY3;tdIxmfGWueTDhZo9tcXOqZXSgZ4F{eGG|ZTCzM|ch[WO2aY\peJkhcW5icnXzdI9ve2VidH:gRWJVNTJ4Mz:ySGcwdWW2Zn;ycYlvKGOxbXLpcoF1cW:w NX3Bc|JSOjN4OUGxOFU>
MCF-7  NVjSOoVZSXCxcITvd4l{KEG|c3H5 NX;0PZRHOjEQvF5CpC=> NUPodpBmPzKq MWDpcohq[mm2czDldZVwdC1iYX7kJFQuV0iWLX3l[IlifGWmIHHwc5B1d3Orcx?= M1\COlI{Pjd3NkSz
hCMEC/D3  MYDBdI9xfG:|aYOgRZN{[Xl? MWqyOe69VQ>? NF7IbVI4Omh? NYK0NJZ2emWmdXPld{BNfHiDIHnu[JVk\WRiYYDvdJRwe2m| NVTpOpFpOjN4NkWxPVg>
Jurkat M2\Eb2Fxd3C2b4Ppd{BCe3OjeR?= NFrGUYEyOi53LUWw{txO NF32bYQycA>? MnHJ[I9{\SCmZYDlcoRmdnSueTDzeZBxemW|c3XzJHNRUC2rbnT1Z4VlKFCjcj20JINt\WG4YXflMEBRSVKSIHPs[YF3[WenLDDEUmEh\nKjZ33lcpRifGmxbjygZY5lKGyxc4Ogc4YhfmmjYnnsbZR6 MYOyN|Q1Ojl5Nh?=
CNE-1 MoL5RZBweHSxc3nzJGF{e2G7 MknQNlDPxE4EoB?= MVmyOIg> Mle0bY5pcWKrdIOgVmFFODBzLXnu[JVk\WRiY3XscEBl\WG2aB?= M4TwflI{PDJ4OEWw
HONE-1 MlrjRZBweHSxc3nzJGF{e2G7 MlnuNlDPxE4EoB?= NVPm[Fk2OjSq M3vSTolvcGmkaYTzJHJCTDByMT3pcoR2[2WmIHPlcIwh\GWjdHi= MofiNlM1OjZ6NUC=
astrocytes cell NYDRUXZjSXCxcITvd4l{KEG|c3H5 MVu0NO69VQ>? M1HWWVZp NX3EPVBOemWmdXPld{Bm[XKueTDhdI9xfG:|aYOgbY5lfWOnZDDifUB{fGG3cn;zdI9zcW6n NHXXcpozOzRzMUe3PC=>
U-937 M3myTGFxd3C2b4Ppd{BCe3OjeR?= MmLJNVDPxE1? NXv2cXp6OzCvaX6= NUXhWVBneHKndnXueJMhXE6ILXnu[JVk\WRibnXjdo9xfG:|aYO= M3PSW|I{PDFyN{S4
MDA-MB-231 NWDBW5Y6SXCxcITvd4l{KEG|c3H5 NYe1dm1yOTByzszN M4f0bVFp MV\pcohq[mm2czDz[Y5{cXSrenH0bY9vKHSxIGTSRWlNKHWyb36gUXRFUCCmb4fuMZJm\3WuYYTpc44> MUiyN|QxQDR{OR?=
HeLa  M{n2TGFxd3C2b4Ppd{BCe3OjeR?= NE\oZo8yODEQvF2= MnHXNog> MXLicI9kc3NiSmLTMVE2KEmwZIXj[ZMhSXCxcITveIlkKEOnbHygSIVifGh? MVGyN|M1PDB2NR?=
Ec109 NVzPfWdsSXCxcITvd4l{KEG|c3H5 MoroNVDPxE1? MmHrOog> NGfU[ZJjdG:la4OgZZBweHSxdHnjJINwdWKrbnH0bY9vKG:oIGTheE1UdWGlTkegZY5lKHKjZHnheIlwdg>? M{PJelI{OzN6NU[4
H460  NHv5SpJCeG:ydH;zbZMhSXO|YYm= NYPXbFliOTEQvF2= MkWyOog> NEXxWoFjdG:la4OgZZBweHSxdHnjJINwdWKrbnH0bY9vKG:oIGTheE1UdWGlTkegZY5lKHKjZHnheIlwdg>? NUDsTldDOjN|M{i1Olg>
HeLa  M{nPdWFxd3C2b4Ppd{BCe3OjeR?= NGThNFM2OM7:TR?= NHXVN|IyNjWq NFrq[mxi[nKxZ3H0[ZPDqEOqbHHtfYRq[S2rbnT1Z4VlKGGyb4D0c5Nqew>? MlzXNlM{ODN6MES=
SK-HEP1 M1PFXWFxd3C2b4Ppd{BCe3OjeR?= MkGyNVAx|ryP MnL5NYg> MW\pcohq[mm2czDDdnQyKGGldHn2ZZRm\CClYYPwZZNmNTNuID23MEAuQCxiLUmsJIFv\CCyb3z5LGFFWC2{aXLvd4UqKHCxbInt[ZJie2V? M4LEclI{OzB{NkWw
QGY7701 NGrxVJVCeG:ydH;zbZMhSXO|YYm= NHX4VoszPc7:TR?= NFv0NGEyNjWq MlrkbY5pcWKrdIOgZYNkfW23bHH0bY9vKG:oIIP1Zk1IOSCyaHHz[UBqdmS3Y3XkJIJ6KESRWDCrJJF2\XKlZYTpci=> NFXJbYgzOzJ2MEC2NS=>
HepG2 NUTXR4pLSXCxcITvd4l{KEG|c3H5 MkS3NlDPxE1? NVHST3hROzCvaX6= MUnpcohq[mm2czD0bIUh\W6qYX7j[YQh[2WubDDk[YF1cCCkeTDjc41jcW6nZDD0doVifG2nboSgc4Yh[XCrZ3XubY4h[W6mIGTSRWlN MXuyN|IzPDJ|OR?=
U87  Mn;JRZBweHSxc3nzJGF{e2G7 Mn3CNlXPxE1? NUT5Tmp6Omh? M4jOT4Rm[3KnYYPld{Bqe2:uaYH1bZJqfGmpZX7pckApUVOOKT3pcoR2[2WmIHHwc5B1d3SrYzDj[YxtKGSnYYToMEBjfXRibn;0JI5m[3KxdHnjJINmdGxiZHXheIg> M33wc|I{OjJ7NkK2
HSC-2 MXLBdI9xfG:|aYOgRZN{[Xl? Mn7ONlUwPTEQvF2= NULINoJLOWh? NYHyRXRxcW6qaXLpeJMhW05vM{itbY5lfWOnZDDjfZRwfG:6aXPpeJk> MlHUNlMyPTV{NEi=
HSC-4 NHvEV25CeG:ydH;zbZMhSXO|YYm= MV[yOU82OM7:TR?= MUGxbC=> NF76ZYFqdmirYnn0d{BUVi1|OD3pcoR2[2WmIHP5eI91d3irY3n0fS=> NUXKTXVPOjNzNUWyOFg>
CL-1 MXPBdI9xfG:|aYOgRZN{[Xl? NWKzN3NtOjEQvF2= MXWxbC=> NH;sSXRjdG:la4OgU3A1PDliaX7keYNm\CClZXzsJIRm[XSq MXSyN|E{OTd6Mh?=
MEL NFqx[GNCeG:ydH;zbZMhSXO|YYm= NWK5RnhmOjEQvF2= MYKyOIg> NVX5bXFtTE2VTx?= NVSyOXlrcW2yYXny[ZMhWDK[Nz3pcoR2[2WmIF3FUEBk\WyuIHHwc5B1d3Orcx?= Mk\WNlMxOTR6OEe=
Bel-7402  NV25UWRPS2G|cHHz[UBC[3SrdnH0bY9vKEG|c3H5 NFK1Upo2OM7:TR?= NH7UeWUzcA>? M{HifIlvcGmkaYTzJHBETS2rbnT1Z4VlKGGwb3nrbZM> M2L3RVI{ODB6N{Sy
Eca-109 MmnmRZBweHSxc3nzJGF{e2G7 MkHuNlXPxE1? M{CwRVMxdWmw MVvpcohq[mm2czDCTk1DOTFvaX7keYNm\CClZXzsJIRm[XSq NFS1fJUzOzB5Nkm2Oy=>
MEL NX72Z4lZSXCxcITvd4l{KEG|c3H5 MnHSNlDPxE1? MlHINYg> NUHHNo55TE2VTx?= NVPLZlZ{cW2yYXny[ZMhWDK[Nz3pcoR2[2WmIF3FUEBk\WyuIHHwc5B1d3Orcx?= M{Gze|I{ODF2OEi3
Bel-7402  NYXURVRGSXCxcITvd4l{KEG|c3H5 NHPMS402OM7:TR?= NWi2NlhEOmh? NHzQOmNqdmirYnn0d{BRS0VvaX7keYNm\CCjbn;pb4l{ M4fOblI{ODB6N{Sy
L929 NYHqbmRuTnWwY4Tpc44hSXO|YYm= M3rnelIvPc7:TR?= MnO0NYg> NVvQPGczcW6lcnXhd4V{KFKLUEGg[ZhxemW|c3nvckBidmRiZYjhZ4Vz[mG2ZXSgWG5H|rFvaX7keYNm\CCvaYTvZ4hwdmS{aXHsJIR6e2[3bnP0bY9vKGGwZDDSU3MheHKxZIXjeIlwdg>? M3jsR|I{ODByNUG4
RCC  MYPD[YxtKF[rYXLpcIl1gSCDc4PhfS=> NGXNN2kyODEQvF2= NFrnfpQzPGh? MXjy[YNwfmW{ZYOgeIhmKH[rYXLpcIl1gSCxZjDj[YxteyCneIDvd4VlKHSxIEG1[E1RT0p{ MYWyNlk6OTR7NB?=
NB2a/d1 MonsRZBweHSxc3nzJGF{e2G7 MVixNFDPxE1? NIq5WWU4Omh? NF3pO4ZifHSnboXheIV{KHO2YYXyc5Nxd3KrbnWtbY5lfWOnZDDjZZNx[XOnIHHjeIl3cXS7LDDQRXJRNCCjbnSgeIF2KGOuZXH2ZYdm M{LGfVIzQTh6NUSx
T cell NXPo[W9ET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF7BRWszPS1zMEFOwG0> M{PHUVI1cA>? NEDUb5dld3OnLXTldIVv\GWwdHz5JIlvcGmkaYTl[EBVKGOnbHygdJJwdGmoZYLheIlwdiCvZXTpZZRm\CC2aILveYdpKHSqZTDjc{1{fGmvdXzheIlwdiC5aYToJIFvfGlvQ1SzJIFv\CCjboTpMWNFOjh? NHn4WVUzOjl6MkWzPC=>
K562 NHrERmNCeG:ydH;zbZMhSXO|YYm= NInKNW8yODEQvF2= MmLMNYg> NFPkcmVjdG:la4OgRYJvd2KjdnnzZ5VuyqCILXnu[JVk\WRiYYDvdJRwe2m| NIfpZ44zOjl5MkO3Ni=>
Jurkat  MWjBdI9xfG:|aYOgRZN{[Xl? NWDJUmM6PDEQvF2= MkTGNYg> MYfhZo9tcXOqZYOgSoF{VC2rbnT1Z4VlKGOjc4Dhd4Uh[WO2aY\heIlwdiCjbnSgZ4VtdCCmZXH0bC=> NUPuOYM5OjJ7NEK3N|g>
BGC-823 MWnBdI9xfG:|aYOgRZN{[Xl? MXGxNFDPxE1? M4S5RVFp MojLdIFzfGmjbHz5JJJme2O3ZYOgZ4VtdHNiYXfhbY5{fCCmYX3h[4Uhd2ZiZHHp[JpmcW5? MVeyNlkzPjV2NR?=
Hep3B M1TiOmFxd3C2b4Ppd{BCe3OjeR?= M{O2SlUx|ryP NEjlVVAycA>? Ml;KZoxw[2u|IHHwc5B1d3OrczDpcoR2[2WmIHL5JGhGT0O| NH;LPXIzOjl{M{G1OC=>
LLC-PK1 Mn:wRZBweHSxc3nzJGF{e2G7 NELIOo8zOM7:TR?= NGe3RYEycA>? NHrD[pVxemW4ZX70d{BkcXOybHH0bY4ucW6mdXPl[EBl\We{YXTheIlwdiCxZjDBeIc2NCCkZXPsbY4uOSxiYX7kJGF1\zF{IIDyc5RmcW6| NF3SOFUzOjh7NkCzOy=>
A549 NEHyS5VCeG:ydH;zbZMhSXO|YYm= NX6wdZNmPTEQvF2= MXKxbC=> MlT0Zoxw[2u|IITo[UBDSUlvaX7keYNm\CCjcH;weI9{cXQEoB?= MkHiNlI5QDd{MUW=
SGC-7901  M13IXWFxd3C2b4Ppd{BCe3OjeR?= M{LEdlEx|ryP NXvzRWdZOjSq NF;lV|NqdmirYnn0d{DPui{Qsj3kbY1mfGi7bHHjdplte2ira3;ubY4ucW6mdXPl[EBieG:ydH;zbZPDqA>? NGrqVpozOjh2OEW5Oy=>
DM6 MlK3RZBweHSxc3nzJGF{e2G7 MoPaNVAx|ryP MXe3Nog> MV3icI9kc3NiYn;0bEBGOkZvMTDhcoQhTTKIdIKtcYVlcWG2ZXSgZ5l1d3SxeHnjbZR6 NXGycXN6OjJ6MkWzNlg>
MCF-7, MDA-MB-468, Caco-2 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlzHOVDPxE1? M1jONVQ5cA>? M{\4OYlvcGmkaYTzJJRp\SClZXzsJIdzd3e2aDDpcohq[mm2aX;uJIlv\HWlZXSgZpkhe2Gyb37pci=> M1LDW|IzQDByOU[4
A2750  NVPhV3B4SXCxcITvd4l{KEG|c3H5 M3zBXVIx|ryP MXqybC=> NWXYdXhbTE2VTx?= MoPwZoxw[2u|IHPhd5Bie2ViY3zlZZZi\2ViZIXybY5oKGinbHXuZYxqdiC2cnXheI1mdnRiYX7kJJJm\HWlZYOgZZV1d3CqYXfpZ{Bk\WyuIHTlZZRp MmjSNlI4QDR|NkO=
U87  NXz4SnJOSXCxcITvd4l{KEG|c3H5 MVuyNO69VQ>? M3LkdFI1cA>? MoH2doVlfWOnczD0bIUh[XCxcITvd4l{KHKjdHWgbY5lfWOnZDDifUBRVEGE MYKyNlc4QDd6MB?=
HT1080 M{D1bmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MonYOVDPxE1? NUC4PHk2P2R? NXHs[IZDcW6qaXLpeJMhfGinIHPlcIwh\3Kxd4ToJIlvcGmkaYTpc44h[2G3c3XkJIJ6KGOxbXLpcoVlKHS{ZXH0cYVvfCCxZjDER2Eh[W6mIF;NVC=> MoHINlI4PDB7OES=
A549  NULiNGdRSXCxcITvd4l{KEG|c3H5 NEfUb3A2OM7:TR?= NGDPWG8zcA>? NVXHd3BZeGG{dHnhcIx6KGSnY4LlZZNmeyC|b3TpeY0he2WuZX7peIUucW6mdXPl[EBieG:ydH;zbZM> NV;V[Xo4OjJ5MkG4NFQ>
Primary OPC M3zQ[GFxd3C2b4Ppd{BCe3OjeR?= M134[FHPxE1? NWG2RY1UPmhxMkTo NH;1bZhz\WS3Y3XzJJRp\SCyZYLj[Y51[WenIH;mJINmdGy|IHnuJIViemy7LTDhcoQhdGG2ZT3hdI9xfG:|aYOvcoVkem:|aYO= NXXtZZNqOjJ5MEezPFU>
PMNs NUD6[2g2SXCxcITvd4l{KEG|c3H5 NUDn[Xc2PDEQvF2= MlfEOog> M3TsNGROW09? M4HYNpJmfmW{c3XkJJRp\SCjbX;1cpQhd2ZiY3zlZZZm\CClYYPwZZNmNTNidH:gcoVieiC4ZXjpZ4xmKGyndnXsdy=> NEP2eHYzOjZ7MkW3Oy=>
A549  MV;BdI9xfG:|aYOgRZN{[Xl? MlnhOVDPxE1? M2\ZU|Fp Mmq2dJJmfmWwdIOgZZBweHSxc3nzJIlv\HWlZXSgZpkhSmGxaIXvd4ll\SCL MnKxNlI3QDd4M{W=
AGS MYLBdI9xfG:|aYOgRZN{[Xl? M{HveFIx|ryP NXWz[WczOTKq M4PhNolvcGmkaYTzJJRp\SCjY4TpeoF1cW:wIH;mJJBzdy2lYYPwZZNmNTNiaX6gdoV{eG:wc3WgeI8hfGinIFX0U2FkKG[{YXP0bY9v MofJNlI3QDd|OUi=
shC9  MnTORZBweHSxc3nzJGF{e2G7 NFXMOG4yOM7:TR?= NE\3Z2wyPmh? NYDNVGxN[my3boTzJHNJUCCneIDy[ZN{cW:wIHnuJJNpSzliY3XscJMh\Xiyb4Pl[EB1dyCnaYTo[ZIhWEFib4KgUHBE NFLkfVEzOjZ2MUC5OC=>
primary MEFs NXT5dFluTnWwY4Tpc44hSXO|YYm= M3jo[lEzcA>? NGrqPJTDqGmwY4LlZZNmeyCndH;wc5Nq\GVvaX7keYNm\CCvaYTvZ4hwdmS{aXHsJI1mdWK{YX7lJIRmeG:uYYLpfoF1cW:w NUHCbpFrOjJ4MUO3Olc>
3T9 MEFs M4Ht[mZ2dmO2aX;uJGF{e2G7 MWexOog> M2HmOYlv[3KnYYPld{BkgXSxY3jyc41mKGNicnXs[YF{\SCjZoTldkBmfG:yb4Pp[IUufHKnYYTt[Y51 NUnrZ5NOOjJ4MUO3Olc>
3T9 MEFs NHzsc|ZHfW6ldHnvckBCe3OjeR?= Mmn0NVhp M1\ZSpVxemWpdXzheIV{KGmwaYTpZZRweiClYYPwZZNmNTliYoX0JIRwf26{ZXf1cIF1\XNiZX\m[YN1d3JiY3HzdIF{\XNiYX\0[ZIh\XSxcH;zbYRmKHS{ZXH0cYVvfA>? NVPie4NtOjJ4MUO3Olc>
MDA-MB-231  NUW1UnVSSXCxcITvd4l{KEG|c3H5 NEToR4wzOM7:TR?= NVvGdXZzPGR? NV7qPXZoemWmdXPld{B1cGViY3XscEBieG:ydH;zbZMhcW6mdXPl[EBjgSCvZYTmc5JucW5idILlZZRu\W62IIfhd{B{cWewaX\pZ4FvfGy7 M1LaPVIzPTl|NESx
C6  MVTBdI9xfG:|aYOgRZN{[Xl? MXuxNO69VQ>? MVuyOIg> MlHWZoxw[2u|IITo[UB{fXCycnXzd4l3\SCnZn\lZ5Qhd2ZidHjlJJBmeHSrZHWgc44hfmmjYnnsbZR6 M3rtc|IzPTh6OUiw
HL-60  MYXBdI9xfG:|aYOgRZN{[Xl? M2fW[VExOM7:TR?= M2Pm[VI1cA>? MknhbY5pcWKrdIOgeIhmKGOnbHygZZBweHSxc3nzJJNmdGWldHXkJEgsMS2vZX70bJltKM7{LTix5qaTPilvZHnncJVkd3C7cnHuc5Nq\GYEoEW= M3HicFIzPTR4Nk[5
HL-60 M2La[GFxd3C2b4Ppd{BCe3OjeR?= MXKxNE05OM7:TR?= M3X4cFRp MoHQbY5pcWKrdIOgWGdJWS2rbnT1Z4VlKGOnbHygZZBweHSxc3nzxsA> M{jOblIzPTJ|MkK5
BCC NFLZ[ZFCeG:ydH;zbZMhSXO|YYm= Ml7UOVDPxE1? Mlf0NYg> NYnFZ3JycW6qaXLpeJMhTEGWUz3t[YRq[XSnZDDndo94fGhiaX7obYJqfGmxbh?= MWOyNlUyQTR|Nh?=
RAW 264.7 M1TWd2Fxd3C2b4Ppd{BCe3OjeR?= Ml3vOVAwOTByzszN NH[4NG4ycA>? M2rtbYNwdmOnboTyZZRqd25vZHXw[Y5l\W62IHnubIljcXS|IFTPUk1qdmS3Y3XkJJJTVkFiY3zlZZZi\2V? NUXpZnBZOjJ2OUG0NlY>
K562 MnXhRZBweHSxc3nzJGF{e2G7 M1myXlI2|ryP NEjDT5UzcA>? MoK1dJJmfmWwdIOgZZBweHSxc3nzJIlv\HWlZXSgZpkh[29vdILlZZRu\W62IIfpeIgh[W23cnXud4lvKEdiYX7kJHRTSUmO M4LIRlIzPDh|N{e3
SGC-7901 NF71bGtCeG:ydH;zbZMhSXO|YYm= MYiyNEDPxE4EoB?= M1HjPVJp NH7hNY1ifHSnboXheIV{KEh{T{NCpI9zKFSQRjFOtU1qdmS3Y3XkJINmdGxiYYDvdJRwe2m|IHHzJJdmdGxiYYOgZ4F{eGG|ZT2zJIFkfGm4aYT5xsA> NHn4SJozOjR5MUW4PS=>
PC3 MX7BdI9xfG:|aYOgRZN{[Xl? NFLoTVgyOM7:TR?= MkDZOIg> MWrjc5VvfGW{czDmcIF3d2OxeHnkMYlv\HWlZXSgZ4F{eGG|ZT3y[YxifGWmIHHwc5B1d3Orcx?= M{TKbVIzPDdzOUe0
SMMC-7721 NGrJflhCeG:ydH;zbZMhSXO|YYm= MofGOVDPxE1? MnrYOFhp M2DrSoF1fGWwdXH0[ZMhd1SULXnu[JVk\WRiYYDvdJRwe2m| MWCyNlQ3PTh|Mx?=
HeLa  NV3CdpNiSXCxcITvd4l{KEG|c3H5 NFG2NYo2OMLizszN MlyzOE85cA>? M1fYbolvcGmkaYTzJHNVWy2rbnT1Z4VlKGyjdHWtdIhie2ViYYDvdJRwfGmlIHX2[Y51ew>? MUGyNlQ3ODVyNB?=
HeLa  MlzLRZBweHSxc3nzJGF{e2G7 MWO1NOKh|ryP MVKxbC=> M2C4UZN2eHC{ZYPz[ZMhfGinIF\SRXAucW6mdXPl[EBi[2O3bYXsZZRqd25ib3[gZY5v\XirbjDWJJBwe2m2aY\lJINmdGy| MVuyNlQ1QTR2MB?=
T47D  NEiy[ohCeG:ydH;zbZMhSXO|YYm= NHr5UokyODEQvF2= NIrvR3cycA>? MWTicI9kc3NidHjlJIdmdmW{YYTpc44hd2ZiRT3jZYQwS1SIMjDifUBUXFN? MUOyNlQxOTF4OB?=
HeLa  MXzBdI9xfG:|aYOgRZN{[Xl? NFjYb2U{OM7:TR?= NXe5cYZ{PGh? MURCpIlv[3KnYYPld{B1cGViZ3Xu[ZJidCClZXzsJJZq[WKrbHn0fUA1QCCqIHHmeIVzKHCqb4Tv[Jlv[W2rYzD0doVifG2nboVCpC=> NIC0Z2wzOjN7NEK0PC=>
HCC M1jOT2Fxd3C2b4Ppd{BCe3OjeR?= NWXkToFkOjBizszNxsA> NFW0ZpUzcA>? M{HiUoF1fGWwdXH0[ZMhfGinIFTIRUBqdmS3Y3XkJIFkfGm4YYTpc44hd2ZiUFHSVC=> NXOzNXliOjJ|NEK3N|I>
mESCs NX2ySYZbSXCxcITvd4l{KEG|c3H5 MUOyMlXPxE1? MoTvNog> Mm\GbY5pcWKrdIOgeIhmKE6jRj3t[YRq[XSnZDDjZZNx[XOnIHHjeIl3[XSrb36= MmDtNlIzQDV{N{S=
EMT-6  MUnDfZRwfG:6aXPpeJkhSXO|YYm= NX;lWZZGOTByzszN NXm3PVBzOWh? NILFVFdx[XK2aXHscJkh[myxY3vl[EBk\WyuIHTlZZRpKGmwZIXj[YQh[nlic3nyZY1me2mwZR?= MYGyNlI2OTl{MR?=
MCF7 NVvPNG5USXCxcITvd4l{KEG|c3H5 NHzQdGI2OMLizszN Mm\XNYg> MnntbY5pcWKrdIOgVGEh[WO2aY\heIVlKGOjc4Dhd4UuOyxiLUmsJIFv\CCyb3z5LGFFWC2{aXLvd4UqKHCxbInt[ZJie2V? M{H5V|IzOjJ|M{S1
K562 NXrUSXlMSXCxcITvd4l{KEG|c3H5 NX7Cd3RJOjBizszNxsA> NFexcIU1QGh? MkGySG1UVw>? NUnRTnhI[myxY3vzJIxieGG2aX7pZk1qdmS3Y3XkJIlvcGmkaYTpc44hd2ZidnnhZoltcXS7IHHu[EBieG:ydH;zbZMhcW6mdXP0bY9v MYGyNlIyPjF3OB?=
Molt4-hyg MkXtRZBweHSxc3nzJGF{e2G7 NFO5dJgyOM7:TR?= M17pcVAvPWh? M1XtZ4Jtd2OtczDmZZJv\XOxbD3pcoR2[2WmIHPhd5Bie2VvMz3sbYtmKGGldHn2bZR6 M{jmTFI3Ojd3OEGx
HeLa NGLvbXdCeG:ydH;zbZMhSXO|YYm= NYTicWFqOTEQvF2= NHPTTWwxNjWq M4jXNIlvcGmkaYTzJIFxd3C2b4Ppd{BqdmS3Y3XkJIJ6KHSqZTDjc41jcW6nZDD0doVifG2nboSge4l1cCCpb33pd4lvKE5iYX7kJHRTSUmO M17qdVIzOTd7Nk[x
Jurkat T MkPCRZBweHSxc3nzJGF{e2G7 MojmN|DPxE1? MV:wMlVp NXKyd4ZtTE2VTx?= MnjVZoxw[2u|IITo[UB7cXKjbT3pcoR2[2WmIHHwc5B1d3Orcx?= NWL5fWRROjJzNUm4PVg>
Neutrophil NVm0cHMzSXCxcITvd4l{KEG|c3H5 MmrpNlDPxE1? M2PlUVAvPWh? Mlv1ZZR1\W63YYTld{B1cGVicILvMYFxd3C2b4TpZ{Bm\m[nY4Sgc4YhVWGUMR?= MYGyOlE6Pjh2NB?=
HCT116 Ml3NRZBweHSxc3nzJGF{e2G7 MY[1NOKh|ryP NITyVoczcA>? M4XTbJJmfmW{c3XzJJN6dmW{Z3nzeIlkKGGyb4D0c5NqeyCnZn\lZ5R{KG:oIHPlcIVkd3irYjDhcoQhVlCFLUG2xsA> MonQNlIyPTl5NUK=
MDA-MB-231  MoXlRZBweHSxc3nzJGF{e2G7 M1P5UFIvPS15LkZOwG0> NETLVWMzcA>? MXXpcohq[mm2czD0bIUh[2WubDDk[YF1cCCxZjDNSGEuVUJvMkOxJINmdGy|IHnu[JVk\WRiYomgV2RVKGmwIHGgZ49v[2WwdILheIlwdiCmZYDlcoRmdnRibXHucoVz MnGyNlIyOTV3Mk[=
LNCaP NHXs[5VCeG:ydH;zbZMhSXO|YYm= NFzRb|c1OM7:TR?= NXvqbHNpOmh? NF\EZ3dqdmirYnn0d{BjfXSnaX6gbY5lfWOnZDDj[YxtKGGyb4D0c5Nqew>? MWqyNlEyPDd4NB?=
MB231 MmDhRZBweHSxc3nzJGF{e2G7 NYXkfFExOTByzszN MWixbC=> MVXEUXNQ MmTmZYJzd2ejdHXzJJRp\SCrbnT1Z5Rqd25ib3[gZ4VtdCCmZXH0bEBjgSCZRVWxJIlvcGmkaYTpc44tKFSUQVnMJJRz\WG2bXXueEwh[W6mIITo[UBkd22kaX7heIlwdg>? NXjWWVc2OjJzMUK5OFA>
HCC38  M2C3fmFxd3C2b4Ppd{BCe3OjeR?= MWixNFDPxE1? NV;CVIdXOWh? MX;EUXNQ NGjuUFFi[nKxZ3H0[ZMhfGinIHnu[JVkfGmxbjDv[kBk\WyuIHTlZZRpKGK7IGfFSVEhcW6qaXLpeIlwdixiVGLBTWwhfHKnYYTt[Y51NCCjbnSgeIhmKGOxbXLpcoF1cW:w MkDUNlIyOTJ7NEC=
MDA-MB231 M4\kRWFxd3C2b4Ppd{BCe3OjeR?= M2fRU|UxyqEQvF2= NYG4NnRGOjSq MYLEUXNQ NUjNbFJp[WK{b3fheIV{KGO3cnP1cYlvNWmwZIXj[YQh[2WubDDk[YF1cA>? NIjnPHczOjFyMUOzOS=>
LNCaP M3Lz[GFxd3C2b4Ppd{BCe3OjeR?= NXXYXZU{PTEEoN88US=> MmfQNlRp MUDEUXNQ M2DIW4Fjem:pYYTld{BkfXKldX3pck1qdmS3Y3XkJINmdGxiZHXheIg> MX:yNlExOTN|NR?=
HCT116 MmrTRZBweHSxc3nzJGF{e2G7 NX\xR5ZJPTEEoN88US=> MnTWNlRp M3X0dGROW09? MUfhZpJw\2G2ZYOgZ5Vz[3WvaX6tbY5lfWOnZDDj[YxtKGSnYYTo MXiyNlExOTN|NR?=
Ishikawa  MnPvRZBweHSxc3nzJGF{e2G7 MXiyOe69VQ>? NUnpN2R7OjSq NX3KVpRnemWmdXPld{Bk\WyuIHTlZZRpKGGwZDDhdI9xfG:|aYOgbY5lfWOnZDDifUBD[WZiQUG= NF7DUJQzOjB6OEmxPC=>
 YD-8  M13ocWFxd3C2b4Ppd{BCe3OjeR?= MV2xNFDPxE1? MVuxbC=> NXzpWmZ7cW6qaXLpeJMhWEyHTz3pcoR2[2WmIHHwc5B1d3Orcx?= NUTRc5lLOjJyOE[xPFM>
eosinophil  NVnufnBrSXCxcITvd4l{KEG|c3H5 MV[5NO69VQ>? NWHHVJlGOjSq MlXybY5pcWKrdIOgZZBweHSxc3nzJIlv\HWlZXSgZpkhTmG|IHHueIljd2S7wrC= MX[yNlA4QTN|NB?=
L929 MoLaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml\FNk42|ryP MWGyOIg> NXLQVJo4cW6qaXLpeJMhfGinIHX4dJJme3Orb36gc4YheC2yM{igZY5lKE6ILd86RkB1dyCjdXft[Y51KFSQRt8xMYlv\HWlZXSgcoVkem:ydH;zbZMh[W6mIHH1eI9xcGGpeR?= NXzTRlRtOjJyMkewPVc>
YD-8  MV;BdI9xfG:|aYOgRZN{[Xl? NYP2N3A4OTByzszN NFr3NmEycA>? NHzvUHljdG:la4OgeIhmKEeVLVjDcE1qdmS3Y3XkJIFxd3C2b4Ppdy=> NYPmPFB1OjJyMkCwO|g>
HBx MXTBdI9xfG:|aYOgRZN{[Xl? M37LT|I2|ryP MkLSOFhp NGrqcHlFVVOR NUT4dpVKemWmdXPl[EBk\WyuIHTlZZRpKGmwZIXj[YQh[nliMz3NRS=> NInXc5UzOjB{MEC3PC=>
U937  MVXBdI9xfG:|aYOgRZN{[Xl? NWrTdllyPTEEoN88US=> M{C0e|Fp MkezbY5pcWKrdIOgTGYucW6mdXPl[EBieG:ydH;zbZPDqA>? MUWyNVk6QDd|MR?=
HL60 Mk\tRZBweHSxc3nzJGF{e2G7 NY\zdmlRPDEQvF2= NWrmOJB4PDCvaX6= NGH5T45FVVOR NF\nRo9jdG:la4OgRm5FSyClb33wc5Vv\HNiaX7keYNmKGW6cH;zeZJmKG:oIIDoc5NxcGG2aXT5cJNmemmwZTDhcoQhTE6DIH\yZYdu\W62YYTpc44> NFvkUGozOTl6M{K5Oi=>
M-14 MoH1RZBweHSxc3nzJGF{e2G7 NUfC[HZOOjYQvF2= M3WwRVAvPWh? M2HKWeKhcW6qaXLpeJMh[m:2aDD0bIUh[3K3ZHWg[Zh1emGldD2gZY5lKGOxbYDveY5lNWmwZIXj[YQh[XCxcITvd4l{ NEfvXI0zOTl3NEm1PS=>
SK-BR-3 NI\lRnFCeG:ydH;zbZMhSXO|YYm= MXK1NOKh|ryP MnXnNog> NX\ab5Fy[myxY3vzJIFxd3C2b4TpZ{BFVkFiZoLh[41mdnSjdHnvckBqdmS3Y3XkJIJ6KGOxbXLpcoF1cW:wIH;mJHNONTF4NDDhcoQhemGmaXH0bY9v MVWyNVkxOTN6Nh?=
MDA-MB-468 MVXBdI9xfG:|aYOgRZN{[Xl? MojoOVDDqM7:TR?= MWWybC=> NX7pNVJ5[myxY3vzJIFxd3C2b4TpZ{BFVkFiZoLh[41mdnSjdHnvckBqdmS3Y3XkJIJ6KGOxbXLpcoF1cW:wIH;mJHNONTF4NDDhcoQhemGmaXH0bY9v NWTnOndMOjF7MEGzPFY>

他の多くの細胞株試験データをご覧になる場合はこちらをクリックして下さい

体内試験 In vivo Z-VAD-FMK administration has been shown previously to be nontoxic and to prevent apoptosis in animal models. Intraperitoneal HK-GBS injection leads to preterm delivery, and pretreatment with Z-VAD-FMK delays preterm delivery in mice. In OVA-sensitized mice,treatment of z-VAD-fmk inhibits allergen-induced leukocyte infiltration. Systemic injection of the pan-caspase inhibitor z-VAD-fmk immediately before OVA challenge reduced inflammatory cell accumulation, mucus hypersecretion, and Th2 cytokine release in OVA-sensitized/challenged mice. Treatment with z-VAD-fmk blocked terminal differentiation of lens epithelial cells and keratinocytes, the differentiation of monocytes into macrophages, and the differentiation of erythroid progenitors. z-VAD-fmk attenuated allergen-induced airway inflammation and hyperreactivity. Treatment with z-VAD-fmk in vivo also prevented subsequent T cell activation ex vivo[7].

お薦めの試験操作(参考用のみ)

細胞試験:

[6]

+ 展開
  • 細胞株: human granulosa cell lines (GC1a, HGL5, COV434)
  • 濃度: 50 μM
  • 反応時間: 48 h
  • 実験の流れ:

    To validate the efficacy of Z-VAD-FMK, three human granulosa cell lines (GC1a, HGL5, COV434) were treated for 48 h with etoposide (50 μg/ml) and/or Z-VAD-FMK (50 μM) under normoxic conditions. To mimic the ischemic phase that occurs after ovarian fragment transplantation, cells were cultured without serum under hypoxia (1 % O2) and treated with Z-VAD-FMK. The metabolic activity of the cells was evaluated by WST-1 assay. Cell viability was determined by FACS analyses. The expression of apoptosis-related molecules was assessed by RT-qPCR and Western blot analyses.


    (参考用のみ)
動物試験:

[7]

+ 展開
  • 動物モデル: CD1 mice
  • 製剤: dissolved in DMSO, diluted in PBS (final concentration of DMSO < 1%)
  • 投薬量: 10 mg/kg
  • 投与方法: i.p.
    (参考用のみ)

溶解度 (25°C)

体外 DMSO 93 mg/mL (198.93 mM)
Water Insoluble
Ethanol Insoluble warmed
体内 左から(NMPから)右の順に溶剤を製品に加えます(文献ではなく、Selleckの実験によるデータ):
2% DMSO+35 %PEG 300+2%Tween 80+ddH2O
混合させたのち直ちに使用することを推奨します。
6mg/mL

* 溶解度測定はSelleck技術部門によって行われており、その他文献に示されている溶解度と差異がある可能性がありますが、同一ロットの生産工程で起きる正常な現象ですからご安心ください。

化学情報

分子量 467.49
化学式

C22H30FN3O7

CAS No. 187389-52-2
保管
in solvent
別名 N/A

便利ツール

モル濃度計算器

モル濃度計算器

求めたい質量、体積または濃度を計算してください。

質量 (g) = 濃度 (mol/L) x 体積 (L) x 分子量 (g/mol)

モル濃度計算器方程式

  • 質量
    濃度
    体積
    分子量

*貯蔵液を準備するとき、常に、オンであるとわかる製品のバッチに特有の分子量を使って、を通してラベルとMSDS/COA(製品ページで利用可能な)。

希釈計算器

希釈計算器

貯蔵液を準備するために必要な希釈率を計算してください。Selleck希釈計算器は、以下の方程式に基づきます:

開始濃度 x 開始体積 = 最終濃度 x 最終体積

希釈の計算式

この方程式は、一般に略語を使われます:C1V1 = C2V2 ( 入力 出力 )

  • C1
    V1
    C2
    V2

常に貯蔵液を準備するとき、小びんラベルとMSDS/COA(オンラインで利用できる)で見つかる製品のバッチに特有の分子量を使ってください。

連続希釈計算器方程式

  • 連続希釈剤

  • 計算結果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量計算器

分子量计算器

そのモル質量と元素組成を計算するために、合成物の化学式を入力してください:

総分子量:g/mol

チップス: 化学式は大文字と小文字の区別ができます。C10H16N2O2 c10h16n2o2

モル濃度計算器

質量 濃度 体積 分子量

技術サポート

ストックの作り方、阻害剤の保管方法、細胞実験や動物実験の際に注意すべき点など、製品を取扱う時に問い合わせが多かった質問に対しては取扱説明書でお答えしています。

Handling Instructions

他に質問がある場合は、お気軽にお問い合わせください。

  • * 必須

よくある質問(FAQ)

  • 質問1:

    Can you suggest an in vivo formulation of S7023 for animal studies?

  • 回答:

    For in vivo study of S7023, The IP formulation is 2% DMSO+35 % PEG 300+2% Tween 80+ddH2O up to 6 mg/ml. The gavage formula is 1%CMC-Na up to 30 mg/ml (suspensions).

  • 質問2:

    What is difference between S7023 & S8102?

  • 回答:

    Unlike S7023, S8102 does not require pretreatment with esterase for in vitro studies. This information was cited from the article: https://www.ncbi.nlm.nih.gov/pubmed/16973565.

Caspaseシグナル伝達経路

相関Caspase製品

Tags: Z-VAD-FMKを買う | Z-VAD-FMK ic50 | Z-VAD-FMK供給者 | Z-VAD-FMKを購入する | Z-VAD-FMK費用 | Z-VAD-FMK生産者 | オーダーZ-VAD-FMK | Z-VAD-FMK化学構造 | Z-VAD-FMK分子量 | Z-VAD-FMK代理店
×
細胞株 試験類型 濃度 培養時間 溶剤類型 活性叙述 PMID